# Cerebrospinal fluid and frontal cortex TMPRSS2 and ACE2 protein levels differ in Down syndrome and Alzheimer's disease.

- **DOI:** [10.1186/s40478-026-02289-9](https://doi.org/10.1186/s40478-026-02289-9)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** Species-resolved profiling identifies distinct DS and AD protein patterns, but small unmatched cohorts prevent firm conclusions about viral susceptibility.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs40478-026-02289-9

## Key claims

1. increased levels of the active TMPRSS2 protease constitute a potential risk factor for enhanced entrance of SARS-CoV-2 into the brain of individuals with DS
   - Support: Tentative
   - Type: Primary finding
   - Basis: cross-sectional protein abundance does not identify catalytic activity, viral entry, or infection susceptibility
   - Location: Discussion, paragraph beginning “Taken together, the results indicate”
2. CSF and frontal cortex TMPRSS2 full-length zymogen and active protease-domain fragment were significantly increased in nDS, but not in dDS
   - Support: Supported
   - Type: Secondary
   - Basis: concordant CSF and cortex differences, constrained by four nDS cortex cases and age imbalance
   - Location: Abstract; Results, Figs. 1 and 3
3. an ~ 80 kDa fragment of ACE2 was significantly reduced in nDS CSF compared to controls, whereas there was a significant decrease in an ACE2 fragment/full-length quotient in both nDS and dDS
   - Support: Tentative
   - Type: Secondary
   - Basis: the dDS quotient interpretation conflicts with the Results wording despite a reported P=0.046
   - Location: Abstract; Results, Fig. 5B–C
4. In AD, frontal cortex levels of the 150 kDa ACE2 full-length species was significantly reduced across all Braak stages
   - Support: Supported
   - Type: Secondary
   - Basis: stage-consistent reported differences, tempered by a seven-case control group and multiple outlier exclusions
   - Location: Abstract; Results, Fig. 8A–B

## Strengths

- **Species-resolved cross-disorder molecular comparison** ACE2 and TMPRSS2 full-length forms and fragments are compared across nDS, dDS, AD, and controls in both CSF and frontal cortex, delineating patterns that total-protein measurements could obscure.
  - Dimension: contribution
  - Location: Abstract; Results, Figs. 1–8
- **Documented biochemical measurement controls** The study reports serial-dilution checks for linear detection, duplicate independent blots, a shared CSF inter-blot normalizer, and vinculin normalization for brain extracts.
  - Dimension: methodological rigour
  - Location: Methods, quantitative fluorescent western blotting
- **Conflicting ACE2 literature addressed** The Discussion presents prior reports of increased, unchanged, and reduced ACE2-related measures in AD and identifies methodological and regional explanations for disagreement.
  - Dimension: positioning
  - Location: Discussion, paragraph beginning “Previous transcriptomic and proteomic studies”

## Limitations

- **Small, unmatched cortex comparison groups** The nDS cortex group contains four cases and is approximately 20 years younger than controls, while dDS cases also differ in age. No covariate-adjusted confounding strategy is reported.
  - Dimension: methodological rigour
  - Location: Methods, DS case demographics; Discussion, limitations paragraph
- **Internal ACE2 reporting contradiction** The dDS ACE2 quotient is described as a reduction that “was not seen” despite P=0.046, whereas the abstract and Fig. 5 title report a reduction in both DS groups.
  - Dimension: reporting
  - Location: Abstract; Results, CSF ACE2 analysis; Fig. 5C
- **Susceptibility claims exceed measured outcomes** The study measures protein abundance but not catalytic activity, blood-brain barrier integrity, viral entry, infection, or clinical susceptibility. Separate cohorts also preclude a direct DS-versus-AD specificity test.
  - Dimension: reporting
  - Location: Discussion, TMPRSS2 interpretation, ACE2 immunoreactivity, and summary paragraphs

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - an ~ 80 kDa fragment of ACE2 was significantly reduced in nDS CSF compared to controls, whereas there was a significant decrease in an ACE2 fragment/full-length quotient in both nDS and dDS: "This quotient confirmed a significant reduction of the cleaved fragment in relation to the unprocessed form in nDS (P = 0.008), which was not seen in dDS (P = 0.046) compared to disomic controls (Fig. 5C)." (Results, CSF ACE2 analysis in DS and AD) vs "P values < 0.05 were considered significant." (Methods, Statistical analysis). The reported dDS quotient P = 0.046 is below the stated 0.05 threshold, contradicting the sentence's denial of a significant reduction. → Not supported by the paper's own data
- **Reporting and transparency:** Noted. The TMPRSS2 cortex legend reports 10 controls versus 11 in the cohort description without explaining the difference, and the study explicitly discloses that it was not preregistered; neither establishes a changed numerical result.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared
- **Reference integrity:** Clean
  - 63 references in manuscript
  - 63 of 63 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
